Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
FDA lifts hold on Amgen's phase 1 obesity study
The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants.
Gabrielle Masson
May 2, 2025 10:10am
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
Apr 23, 2025 7:25am
Pfizer axes oral GLP-1 asset, blowing hole in obesity plan
Apr 14, 2025 7:34am
Novo inks $1B deal for Lexicon’s preclinical obesity prospect
Mar 28, 2025 7:30am
Ascletis slashes funds for former core programs in obesity pivot
Mar 26, 2025 10:00am
Mira seeks to buy Skny for obesity, smoking cessation asset
Mar 24, 2025 10:08am
